177Lu-PSMA-617 in Metastatic Castration Resistant Prostate Cancer (mCRPC) With Bone Marrow Involvement and Cytopenia

Phase 2

Not yet recruiting

• Conditions: Metastatic Castration Resistant Prostate Cancer; Bone Marrow; Cytopenia
• Interventions: Drug: 177Lu-PSMA-617

• Registration Number: NCT07025512
• Lead Sponsor: M.D. Anderson Cancer Center

Brief Summary

To control mCRPC that has spread to the bone marrow. The safety and effects of this treatment will also be studied.

Detailed Description

Not available

Study Timeline

• Status Verified: 2025-06
• Study First Submitted: 2025-06-06
• Study First Submitted QC: 2025-06-09
• Last Update Submitted: 2025-06-09
• Study First Posted: 2025-06-17
• Last Update Posted: 2025-06-17
• Study Start: 2025-12-03
• Primary Completion: 2027-06-30
• Study Completion: 2029-06-30

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: Male
• Target Recruitment: 40

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
SingleArm	177Lu-PSMA-617	Treatment with Lu-PSMA-617 IV Q6W

Primary Outcome Measures

Name	Time	Method
Safety and adverse events (AEs).	Through study completion; an average of 1 year	Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0

Trial Locations

Locations (1)

MD Anderson Cancer Center; 🇺🇸 Houston, Texas, United States